Regeneron Pharmaceuticals
stock was tumbling after the medicine maker reported lower sales of its Eylea treatment than Wall Street was anticipating for the fourth quarter.
In a preliminary update on its fourth quarter on Monday,
Regeneron
(ticker: REGN) said fourth-quarter sales of Eylea were $1.5 billion. The consensus call among analysts tracked by FactSet was for $1.64 billion, while the year-earlier figure was $1.55 billion.
Xerox has agreed to purchase printer maker Lexmark Worldwide from a consortium of Asian buyers in a deal valued at...
U.Right this moment - The value of (BTC) continues to fall, dropping almost 15% in simply six days, which is...
Traders seeking to supercharge their portfolios typically profit from a broader inventory search. One easy approach to do this is...
© 2024 Fortune Media IP Restricted. All Rights Reserved. Use of this web site constitutes acceptance of our Phrases of...
Investing.com -- Shares of Kooth (LON:) jumped over 9% on Tuesday after the digital psychological well being service firm mentioned...
Get the latest news and follow the coverage of Investing, World News, Stocks, Market Analysis, Business & Financial News, and more from the top trusted sources.
